AbbVie Inc. (ABBV)
Bank of Hawaii Sells 3,585 Shares of AbbVie Inc. $ABBV
Bank of Hawaii reduced its position in shares of AbbVie Inc. (NYSE: ABBV) by 10.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,369 shares of the company's stock after selling 3,585 shares during the period. Bank of Hawaii's
The Best Dividend Stocks to Buy and Hold Forever
Johnson & Johnson and AbbVie have successful, diversified healthcare businesses. History suggests they will maintain their dividend programs for many more years.
Josh Brown: Biotech growth stocks immune to disruption risk
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC's Halftime Report this week about large-cap biotech: “These are growth stocks where you don't have to worry about disruption.
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.
AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue?
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA review.
These 3 Cash Flow Machines Provide Stability in Uncertain Markets
When times get tough for companies, cash flow is an essential element that can determine viability through a challenging market. Simply put, if a firm does not have the ability to meet its near-term obligations with its cash on hand, it risks collapsing.
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, AbbVie (ABBV) closed at $232.35, indicating a -1.63% shift from the previous trading day.
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
